ArticleCell reports2017
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.Frontiers in oncology · 2024Pooled it
- Androgen receptor drives divergent chromatin accessibility programs in benign and malignant prostate epithelial cells.Nucleic acids research · 2026Article
- Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2.Molecular oncology · 2026Article
- Integrated multi-omics profiling uncovers the epigenetic, transcriptional, and metabolic landscape of prostate cancer progression.BMC cancer · 2026Article
- Mechanism and therapeutic significance of ARV-110 combined with a PDGFR inhibitor for the induction of apoptosis in castration-resistant prostate cancer cells through the ROS/JNK pathway.Cell death & disease · 2026Article
- Chromatin regulatorsChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Review
- Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis.Molecular oncology · 2025Article
- Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer.Oncogene · 2025Review
- Coregulators determine androgen receptor activity in prostate cancer.Bioscience reports · 2025Review
- Combination of PSMA targeting alpha-emitting radioligand [Medical oncology (Northwood, London, England) · 2025Article
- Prostate cancer epigenetics - from pathophysiology to clinical application.Nature reviews. Urology · 2025Review
- Understanding Enzalutamide-Resistance Based on a Functional Single-Cell Approach.The Prostate · 2025Article
- ATAD2 Drives Prostate Cancer Progression to Metastasis.Molecular cancer research : MCR · 2025Article
- Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer.Translational oncology · 2025Review
- Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer.Communications biology · 2025Article
- PROTAC technology for prostate cancer treatment.Acta materia medica · 2025Article
- Coactivator networks orchestrating noncanonical AR programs in enzalutamide-resistant CRPC.Frontiers in oncology · 2025Review
- NFE2 and PF4 as biomarkers for BET inhibition-induced thrombocytopenia in preclinical and clinical studies.Frontiers in medicine · 2025Article
- Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 19 institutions in 6 countries.
Alfonso UrbanucciCentre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, Forskningsparken, University of Oslo, 21 0349 Oslo, Norway; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway. Electronic address: alfonsourbanucci@gmail.com.
Stefan J BarfeldCentre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, Forskningsparken, University of Oslo, 21 0349 Oslo, Norway.
Ville KytöläProstate Cancer Research Center, Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere and Tampere University of Technology, 33520 Tampere, Finland.
Harri M ItkonenCentre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, Forskningsparken, University of Oslo, 21 0349 Oslo, Norway.
Ilsa M ColemanDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Daniel VodákDepartment of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway.
Liisa SjöblomProstate Cancer Research Center, Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere and Fimlab Laboratories, Tampere University Hospital, 33520 Tampere, Finland.
Xia ShengDepartment of Biosciences, University of Oslo, 0316 Oslo, Norway.
Teemu TolonenDepartment of Pathology, Fimlab Laboratories, Tampere University Hospital, 33520 Tampere, Finland.
Sarah MinnerUniversity Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
Christoph BurdelskiGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Kati K KivinummiProstate Cancer Research Center, Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere and Tampere University of Technology, 33520 Tampere, Finland.
Annika KohvakkaProstate Cancer Research Center, Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere and Fimlab Laboratories, Tampere University Hospital, 33520 Tampere, Finland.
Steven KregelDepartment of Surgery - Section of Urology, University of Chicago, Chicago, IL 60637, USA; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109-0940, USA.
Mandeep TakharResearch and Development, GenomeDx Biosciences, Vancouver, BC V6B 1B8, Canada.
Mohammed AlshalalfaResearch and Development, GenomeDx Biosciences, Vancouver, BC V6B 1B8, Canada.
Elai DavicioniResearch and Development, GenomeDx Biosciences, Vancouver, BC V6B 1B8, Canada.
Nicholas ErhoResearch and Development, GenomeDx Biosciences, Vancouver, BC V6B 1B8, Canada.
Paul LloydDepartment of Medicine, University of California at San Francisco, San Francisco, CA 94143-0410, USA; Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA 94143-0981, USA.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, Rochester, MN 55902, USA.
Ashley E RossBrady Urological Institute, Johns Hopkins Medical Institute, Baltimore, MD 21287, USA.
Edward M SchaefferDepartment of Urology, Northwestern University, Feinberg School of Medicine, 303 East Chicago Avenue, Tarry 16-703, Chicago, IL 60611-3008, USA.
Donald J Vander GriendDepartment of Surgery - Section of Urology, University of Chicago, Chicago, IL 60637, USA.
Stefan KnappNuffield Department of Clinical Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, UK; Institute for Pharmaceutical Chemistry, Goethe-University Frankfurt, Campus Riedberg, Max-von Laue Strasse 9, 60438 Frankfurt am Main, Germany.
Eva CoreyDepartment of Urology, University of Washington, Seattle, WA 98195, USA.
Felix Y FengDepartment of Medicine, University of California at San Francisco, San Francisco, CA 94143-0410, USA; Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA 94143-0981, USA; Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94115, USA.
Peter S NelsonDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Urology, University of Washington, Seattle, WA 98195, USA; Department of Pathology, University of Washington, Seattle, WA 98195, USA.
Fahri SaatciogluDepartment of Biosciences, University of Oslo, 0316 Oslo, Norway; Institute for Cancer Genetics and Informatics, Oslo University Hospital, 0424 Oslo, Norway.
Karen E KnudsenSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Teuvo L J TammelaProstate Cancer Research Center and Department of Urology, University of Tampere and Tampere University Hospital, 33014 Tampere, Finland.
Guido SauterUniversity Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
Thorsten SchlommMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg 20095, Germany.
Matti NykterProstate Cancer Research Center, Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere and Tampere University of Technology, 33520 Tampere, Finland.
Tapio VisakorpiProstate Cancer Research Center, Institute of Biosciences and Medical Technology (BioMediTech), University of Tampere and Fimlab Laboratories, Tampere University Hospital, 33520 Tampere, Finland.
Ian G MillsCentre for Molecular Medicine Norway, Nordic European Molecular Biology Laboratory Partnership, Forskningsparken, University of Oslo, 21 0349 Oslo, Norway; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway; PCUK Movember Centre of Excellence, CCRCB, Queen's University, Belfast BT7 1NN, Northern Ireland, UK. Electronic address: i.g.mills@ncmm.uio.no.
University of Oslo · NOGenome British Columbia · CATampere University · FIUniversität Hamburg · DEFimlab (Finland) · FIFred Hutch Cancer Center · USTampere University Hospital · FIGoethe University Frankfurt · DEMayo Clinic in Arizona · USNorthwestern University · USOslo University Hospital · NOQueen's University Belfast · GBSidney Kimmel Cancer Center · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity Medical Center Hamburg-Eppendorf · DEUniversity of California, San Francisco · USUniversity of Chicago · USUniversity of Michigan–Ann Arbor · USUniversity of Washington · US
Funding
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1MSteroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Steven P. Balk · 2013 to 2026
$25.0MUSP22 Function in Advanced Prostate CancerR01CA182569 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KNUDSEN, KAREN E, MCMAHON, STEVEN B. · 2015 to 2019
$2.4MSWI/SNF dysregulation in development and diseaseR01CA159945 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KNUDSEN, KAREN E · 2012 to 2016
$1.6MMedical Research Council MC_PC_13073NCI NIH HHS P01 CA163227NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA159945NCI NIH HHS R01 CA182569Wellcome Trust
Abstract
Global changes in chromatin accessibility may drive cancer progression by reprogramming transcription factor (TF) binding. In addition, histone acetylation readers such as bromodomain-containing protein 4 (BRD4) have been shown to associate with these TFs and contribute to aggressive cancers including prostate cancer (PC). Here, we show that chromatin accessibility defines castration-resistant prostate cancer (CRPC). We show that the deregulation of androgen receptor (AR) expression is a driver of chromatin relaxation and that AR/androgen-regulated bromodomain-containing proteins (BRDs) mediate this effect. We also report that BRDs are overexpressed in CRPCs and that ATAD2 and BRD2 have prognostic value. Finally, we developed gene stratification signature (BROMO-10) for bromodomain response and PC prognostication, to inform current and future trials with drugs targeting these processes. Our findings provide a compelling rational for combination therapy targeting bromodomains in selected patients in which BRD-mediated TF binding is enhanced or modified as cancer progresses.
Indexed as
Chromatin Assembly and DisassemblyGene Expression Regulation, NeoplasticATPases Associated with Diverse Cellular ActivitiesBromodomain Containing ProteinsChromatinDNA-Binding ProteinsHumansMaleNeoplasm ProteinsProstatic Neoplasms, Castration-ResistantProtein Serine-Threonine KinasesReceptors, AndrogenTranscription FactorsATAD2 protein, humanATPases Associated with Diverse Cellular ActivitiesBRD2 protein, humanBromodomain Containing ProteinsChromatinDNA-Binding ProteinsNeoplasm ProteinsProtein Serine-Threonine KinasesReceptors, AndrogenTranscription Factorsandrogen receptorATAD2BRD2BRD4BROMO-10bromodomain inhibitorcastration-resistant prostate cancerchromatin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.